Aagama Exports LLP

Aagama Exports LLP is a pharmaceutical exporter based in Hyderabad, Telangana, India. Established on August 22, 2019, the company operates under the Corporate Identification Number (CIN) AAQ-3386. The registered office is located at Plot 335, HMT Swarna Puri Colony, Ameenpur, Hyderabad, Telangana, 502032. The firm's total obligation of contribution is ₹0.10 million, indicating a modest capital base. As of the latest available data, the company has two active designated partners: Yerrapragada Kusuma Madhavi and Venkata Sai Ramya Ravinuthala. Financial details such as annual revenue and employee count are not publicly disclosed. The company's official website is aagamaexports.com.

Aagama Exports LLP does not own or operate any manufacturing facilities. The company focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products are sourced from third-party manufacturers, as evidenced by their product offerings in activated carbon, chemicals, and IR 64 parboiled rice. The absence of in-house manufacturing suggests a reliance on contract manufacturing arrangements to fulfill export orders.

The leadership team of Aagama Exports LLP comprises two designated partners:

• Yerrapragada Kusuma Madhavi: Appointed on August 22, 2019, she has been associated with the company since its inception.

• Venkata Sai Ramya Ravinuthala: Joined as a designated partner on July 17, 2025, indicating a recent addition to the leadership team.

There is no publicly available information regarding other key executives or their specific roles within the company.

Aagama Exports LLP's export activities are primarily focused on markets in South Asia, notably Bangladesh and Sri Lanka. The company's trade data indicates significant export volumes to these countries, with Bangladesh being a major destination. However, there is no publicly available information regarding the company's presence or regulatory approvals in other regulated markets such as the United States, European Union, United Kingdom, Australia, or Japan. This suggests that Aagama Exports LLP's operations are currently concentrated in the South Asian region.

Aagama Exports LLP has demonstrated a strong presence in emerging markets, particularly in South Asia. The company's export data highlights substantial trade with Bangladesh and Sri Lanka, indicating a strategic focus on these regions. While there is no specific information regarding the company's activities in Africa, Latin America, or Southeast Asia, the existing trade patterns suggest potential for expansion into these emerging markets. The company's adherence to international quality standards, as evidenced by its product offerings, may facilitate entry into these regions.

Aagama Exports LLP's geographic strategy appears to be concentrated in South Asia, with a particular emphasis on Bangladesh and Sri Lanka. The company's export data indicates significant trade volumes with these countries, suggesting a focused market approach. This concentration may expose the company to regional risks, including economic fluctuations and regulatory changes. Diversifying into other emerging markets could mitigate such risks and provide growth opportunities.

There is no publicly available information regarding Aagama Exports LLP's registration with the U.S. Food and Drug Administration (FDA), approval of Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. This absence suggests that the company may not currently export pharmaceutical products to the United States or may not have pursued FDA approvals for its products.

Aagama Exports LLP's product offerings include activated carbon and chemicals, which are not pharmaceutical products. Therefore, there is no publicly available information regarding the company's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's focus on non-pharmaceutical products may limit its engagement with these specific certifications.

As a pharmaceutical exporter based in India, Aagama Exports LLP is subject to regulations set by the Central Drugs Standard Control Organisation (CDSCO). However, there is no publicly available information regarding the company's manufacturing licenses, approvals from state drug controllers, or export No Objection Certificates (NOCs). The absence of such information may indicate limited public disclosure or a focus on non-pharmaceutical exports.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Aagama Exports LLP. This lack of information suggests that the company has not faced significant regulatory actions in the public domain.

Aagama Exports LLP operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors are not identified in the available data, the company's trade patterns indicate competition with other exporters in the South Asian region. The absence of in-house manufacturing may position the company differently compared to competitors with integrated manufacturing capabilities.

Aagama Exports LLP's key differentiators include its focus on non-pharmaceutical products such as activated carbon and chemicals, which may appeal to a different customer base compared to traditional pharmaceutical exporters. Additionally, the company's concentration on South Asian markets allows for specialized market knowledge and relationships.

Aagama Exports LLP's current strategic direction appears to be centered on exporting non-pharmaceutical products to South Asian markets. The company's future outlook may involve expanding its product portfolio to include pharmaceutical formulations and exploring new markets to diversify its revenue streams.

Aagama Exports LLP's track record in exporting non-pharmaceutical products is demonstrated by its trade data, indicating consistent export volumes to Bangladesh and Sri Lanka. The company's reliance on third-party manufacturers for pharmaceutical products suggests a need for careful evaluation of supplier reliability and product quality.

Importers should verify the following certifications when considering products from Aagama Exports LLP:

• FDA Registration: To ensure compliance with U.S. regulations for pharmaceutical products.

• WHO-GMP: To confirm adherence to international manufacturing standards.

• EU GMP: To verify compliance with European manufacturing practices.

• ISO Certifications: To assess the company's quality management systems.

Each certification can typically be verified through the issuing authority's official website or by requesting documentation directly from the company.

When conducting due diligence on Aagama Exports LLP, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's compliance with relevant regulatory bodies in target markets.

• Assess Supplier Relationships: Evaluate the reliability and quality standards of third-party manufacturers.

• Review Financial Stability: Analyze available financial statements to assess the company's financial health.

• Check for Regulatory Actions: Investigate any past or pending regulatory actions against the company.

• Evaluate Market Reputation: Seek feedback from existing customers and partners regarding the company's performance.

Red flags to watch for include a lack of transparency in financial reporting, absence of necessary certifications, and any history of regulatory non-compliance. Recommended pre-order checks involve verifying product quality through samples, assessing shipping and delivery capabilities, and ensuring clear communication channels.